O	0	1	A
O	2	12	randomized
O	12	13	,
O	14	19	phase
O	20	22	II
O	22	23	,
O	24	29	three
O	29	30	-
O	30	33	arm
O	34	39	study
O	40	42	of
O	43	46	two
O	47	56	schedules
O	57	59	of
B-intervention	60	71	ixabepilone
O	72	74	or
B-control	75	85	paclitaxel
I-control	86	90	plus
I-control	91	102	bevacizumab
O	103	105	as
O	106	111	first
O	111	112	-
O	112	116	line
O	117	124	therapy
O	125	128	for
O	129	139	metastatic
O	140	146	breast
O	147	153	cancer
O	153	154	.

O	155	158	The
O	159	162	aim
O	163	165	of
O	166	170	this
O	171	176	phase
O	177	179	II
O	180	185	trial
O	186	189	was
O	190	192	to
O	193	201	estimate
O	202	205	the
O	206	215	objective
O	216	224	response
O	225	229	rate
O	230	231	(
O	231	234	ORR
O	234	235	)
O	236	238	of
O	239	242	two
O	243	252	different
O	253	262	schedules
O	263	265	of
O	266	277	ixabepilone
O	278	279	[
O	279	285	weekly
O	286	288	or
O	289	294	every
O	295	296	3
O	297	302	weeks
O	303	304	(
O	304	307	Q3W
O	307	308	)
O	308	309	]
O	310	318	combined
O	319	323	with
O	324	335	bevacizumab
O	335	336	,
O	337	345	relative
O	346	348	to
O	349	350	a
O	351	360	reference
O	361	364	arm
O	365	367	of
O	368	374	weekly
O	375	385	paclitaxel
O	386	389	and
O	390	401	bevacizumab
O	401	402	.

B-eligibility	403	411	Patients
I-eligibility	412	416	with
I-eligibility	417	422	human
I-eligibility	423	432	epidermal
I-eligibility	433	439	growth
I-eligibility	440	446	factor
I-eligibility	447	455	receptor
I-eligibility	456	457	2
I-eligibility	457	458	-
I-eligibility	458	464	normal
I-eligibility	464	465	,
I-eligibility	466	478	chemotherapy
I-eligibility	478	479	-
I-eligibility	479	481	na
I-eligibility	481	482	ï
I-eligibility	482	484	ve
I-eligibility	485	495	metastatic
I-eligibility	496	502	breast
I-eligibility	503	509	cancer
I-eligibility	510	511	(
I-eligibility	511	514	MBC
I-eligibility	514	515	)
O	516	520	were
O	521	531	randomized
O	532	533	3
O	533	534	:
O	534	535	3
O	535	536	:
O	536	537	2
O	538	540	to
O	541	552	ixabepilone
O	553	555	16
O	556	558	mg
O	558	559	/
O	559	560	m
O	560	561	(
O	561	562	2
O	562	563	)
O	564	570	weekly
O	571	575	plus
O	576	587	bevacizumab
O	588	590	10
O	591	593	mg
O	593	594	/
O	594	596	kg
O	597	600	Q2W
O	601	602	(
O	602	605	Arm
O	606	607	A
O	607	608	:
O	609	610	n
O	611	612	=
O	613	615	46
O	615	616	)
O	616	617	;
O	618	629	ixabepilone
O	630	632	40
O	633	635	mg
O	635	636	/
O	636	637	m
O	637	638	(
O	638	639	2
O	639	640	)
O	641	644	Q3W
O	645	646	(
O	646	653	reduced
O	654	656	to
O	657	659	32
O	660	662	mg
O	662	663	/
O	663	664	m
O	664	665	(
O	665	666	2
O	666	667	)
O	668	673	after
O	674	678	four
O	679	685	cycles
O	686	688	of
O	689	698	treatment
O	698	699	)
O	700	704	plus
O	705	716	bevacizumab
O	717	719	15
O	720	722	mg
O	722	723	/
O	723	725	kg
O	726	729	Q3W
O	730	731	(
O	731	734	Arm
O	735	736	B
O	736	737	:
O	738	739	n
O	740	741	=
O	742	744	45
O	744	745	)
O	745	746	;
O	747	749	or
O	750	760	paclitaxel
O	761	763	90
O	764	766	mg
O	766	767	/
O	767	768	m
O	768	769	(
O	769	770	2
O	770	771	)
O	772	778	weekly
O	779	783	plus
O	784	795	bevacizumab
O	796	798	10
O	799	801	mg
O	801	802	/
O	802	804	kg
O	805	816	intravenous
O	817	825	infusion
O	826	829	Q2W
O	830	831	(
O	831	834	Arm
O	835	836	C
O	836	837	:
O	838	839	n
O	840	841	=
O	842	844	32
O	844	845	)
O	845	846	.

O	847	849	Of
B-total-participants	850	853	123
O	854	864	randomized
O	865	873	patients
O	873	874	,
B-total-participants	875	878	122
O	879	883	were
O	884	891	treated
O	891	892	.

O	893	896	All
O	897	901	were
O	902	910	followed
O	911	914	for
O	915	916	≥
O	916	918	19
O	919	925	months
O	925	926	;
O	927	928	5
O	929	930	%
O	931	933	of
O	934	942	patients
O	943	951	remained
O	952	954	on
O	955	960	study
O	961	970	treatment
O	971	973	at
O	974	977	the
O	978	982	time
O	983	985	of
O	986	990	this
O	991	999	analysis
O	999	1000	.

B-outcome	1001	1006	Grade
I-outcome	1007	1008	3
I-outcome	1009	1011	or
I-outcome	1012	1013	4
I-outcome	1014	1025	neutropenia
O	1026	1029	was
O	1030	1034	more
O	1035	1041	common
O	1042	1044	in
O	1045	1048	Arm
O	1049	1050	B
O	1051	1052	(
B-iv-bin-percent	1052	1054	60
I-iv-bin-percent	1055	1056	%
O	1056	1057	)
O	1058	1062	than
O	1063	1067	Arms
O	1068	1069	A
O	1070	1071	(
B-iv-bin-percent	1071	1073	16
I-iv-bin-percent	1074	1075	%
O	1075	1076	)
O	1077	1079	or
O	1080	1081	C
O	1082	1083	(
B-cv-bin-percent	1083	1085	22
I-cv-bin-percent	1086	1087	%
O	1087	1088	)
O	1088	1089	;
O	1090	1095	other
O	1096	1103	adverse
O	1104	1110	events
O	1111	1115	were
O	1116	1123	similar
O	1123	1124	.

O	1125	1128	The
O	1129	1141	investigator
O	1141	1142	-
O	1142	1150	assessed
B-outcome	1151	1154	ORR
O	1155	1158	was
B-iv-bin-percent	1159	1161	48
O	1161	1162	,
B-iv-bin-percent	1163	1165	71
O	1165	1166	,
O	1167	1170	and
B-cv-bin-percent	1171	1173	63
I-cv-bin-percent	1174	1175	%
O	1176	1179	for
O	1180	1184	Arms
O	1185	1186	A
O	1186	1187	,
O	1188	1189	B
O	1189	1190	,
O	1191	1194	and
O	1195	1196	C
O	1196	1197	,
O	1198	1210	respectively
O	1210	1211	.

B-outcome	1212	1218	Median
I-outcome	1219	1230	progression
I-outcome	1230	1231	-
I-outcome	1231	1235	free
I-outcome	1236	1244	survival
O	1245	1246	(
O	1246	1256	randomized
O	1257	1265	patients
O	1265	1266	)
O	1267	1270	was
B-iv-cont-median	1271	1272	9
I-iv-cont-median	1272	1273	.
I-iv-cont-median	1273	1274	6
I-iv-cont-median	1275	1281	months
O	1282	1284	in
O	1285	1288	Arm
O	1289	1290	A
O	1290	1291	,
B-iv-cont-median	1292	1294	11
I-iv-cont-median	1294	1295	.
I-iv-cont-median	1295	1296	9
I-iv-cont-median	1297	1303	months
O	1304	1306	in
O	1307	1310	Arm
O	1311	1312	B
O	1312	1313	,
O	1314	1317	and
B-cv-cont-median	1318	1320	13
I-cv-cont-median	1320	1321	.
I-cv-cont-median	1321	1322	5
I-cv-cont-median	1323	1329	months
O	1330	1332	in
O	1333	1336	Arm
O	1337	1338	C
O	1338	1339	.

O	1340	1342	In
O	1343	1353	conclusion
O	1353	1354	,
O	1355	1366	ixabepilone
O	1367	1370	Q3W
O	1371	1375	plus
O	1376	1387	bevacizumab
O	1388	1391	has
O	1392	1400	clinical
O	1401	1409	activity
O	1410	1412	as
O	1413	1418	first
O	1418	1419	-
O	1419	1423	line
O	1424	1431	therapy
O	1432	1435	for
O	1436	1439	MBC
O	1440	1448	relative
O	1449	1451	to
O	1452	1462	paclitaxel
O	1463	1467	plus
O	1468	1479	bevacizumab
O	1479	1480	,
O	1481	1484	but
O	1485	1489	with
O	1490	1503	significantly
O	1504	1511	greater
O	1512	1516	risk
O	1517	1519	of
O	1520	1525	grade
O	1526	1527	3
O	1528	1530	or
O	1531	1532	4
O	1533	1544	neutropenia
O	1544	1545	.

O	1546	1548	In
O	1549	1557	addition
O	1557	1558	,
O	1559	1564	these
O	1565	1569	data
O	1570	1577	suggest
O	1578	1582	that
O	1583	1589	weekly
O	1590	1596	dosing
O	1597	1599	of
O	1600	1611	ixabepilone
O	1612	1615	may
O	1616	1618	be
O	1619	1623	less
O	1624	1630	active
O	1631	1635	than
O	1636	1639	Q3W
O	1640	1646	dosing
O	1646	1647	,
O	1648	1651	but
O	1652	1656	with
O	1657	1661	less
O	1662	1673	neutropenia
O	1673	1674	.
